Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics (2021)
- Authors:
- USP affiliated authors: SAGGIORO, FABIANO PINTO - SVOI ; REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP ; SOUZA, LUIZ PAULO CHAVES DE - FMRP ; MELO, CAMILA MORAIS - FMRP
- Unidades: SVOI; FMRP
- DOI: 10.3390/genes12121900
- Subjects: NEOPLASIAS PROSTÁTICAS; IMUNOTERAPIA; ONCOGENES; GENES SUPRESSORES DE TUMOR; MUTAÇÃO GENÉTICA; BIOMARCADORES
- Keywords: Castrate-resistant prostate cancer; Immunotherapy; Immune evasion; Tumor microenvironment; Oncogenes; Tumor suppressor genes; Mouse models of cancer; Epigenomics; Plasticity; Chromatin modification
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
SOUZA, Luiz Paulo Chaves de et al. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes, v. 12, n. 12, p. 1-18, 2021Tradução . . Disponível em: https://doi.org/10.3390/genes12121900. Acesso em: 31 dez. 2025. -
APA
Souza, L. P. C. de, Melo, C. M., Saggioro, F. P., Reis, R. B. dos, & Squire, J. A. (2021). Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes, 12( 12), 1-18. doi:10.3390/genes12121900 -
NLM
Souza LPC de, Melo CM, Saggioro FP, Reis RB dos, Squire JA. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics [Internet]. Genes. 2021 ; 12( 12): 1-18.[citado 2025 dez. 31 ] Available from: https://doi.org/10.3390/genes12121900 -
Vancouver
Souza LPC de, Melo CM, Saggioro FP, Reis RB dos, Squire JA. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics [Internet]. Genes. 2021 ; 12( 12): 1-18.[citado 2025 dez. 31 ] Available from: https://doi.org/10.3390/genes12121900 - Emerging role of PTEN loss in evasion of the immune response to tumours
- ZEB1 expression is associated with the PTEN loss and TMPRSS2 ERG fusion immune evasion phenotype in prostate cancer
- TCGA analysis identifies distinct genomic features of oncogenic progression and outcome associated with hemizygous PTEN loss tumors
- The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer
- Analysis of the relationships between ZEB1, PTEN loss, TMPRSS2-ERG fusion and immune response biomarkers in Prostate Cancer
- Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
- PTEN loss associates with STAT1/3 expression and intra-tumoral CD8+ density in prostate cancer
- Quantitative measurement of PTEN loss improves risk assessment in prostate cancer
- Investigating the role of SNAI1 and ZEB1 expression in prostate cancer progression and immune modulation of the tumor microenvironment
- A expressão dos marcadores de transição epitélio-mesenquimal SNAI1 e o ZEB1 resulta em alterações transcricionais para promover progressão tumoral e evasão imune no câncer de próstata
Informações sobre o DOI: 10.3390/genes12121900 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003074056.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
